Research institutions seeking to buy CJC-1295 No DAC in the USA require rigorous analytical standards, verifiable sequence identity, and guaranteed lot-to-lot consistency. As a synthetic 29-amino-acid growth hormone-releasing hormone (GHRH) analog, CJC-1295 No DAC—frequently designated as Modified GRF 1-29—is widely investigated in preclinical models exploring physiological growth hormone dynamics. PX1 Research supplies high-purity, USA-manufactured CJC-1295 No DAC supported by comprehensive analytical documentation strictly for in vitro and laboratory research applications.
Research institutions seeking to buy CJC-1295 No DAC in the USA require rigorous analytical standards, verifiable sequence identity, and guaranteed lot-to-lot consistency. As a synthetic 29-amino-acid growth hormone-releasing hormone (GHRH) analog, CJC-1295 No DAC—frequently designated as Modified GRF 1-29—is widely investigated in preclinical models exploring physiological growth hormone dynamics. PX1 Research supplies high-purity, USA-manufactured CJC-1295 No DAC supported by comprehensive analytical documentation strictly for in vitro and laboratory research applications.
Researchers looking to buy CJC-1295 No DAC in the USA can source analytical-grade compounds directly from PX1 Research. Manufactured in domestic GMP-compliant facilities, our CJC-1295 No DAC undergoes rigorous third-party ISO 17025 lab verification, including RP-HPLC purity testing and mass spectrometry, ensuring verified sequence integrity and batch-to-batch consistency exclusively for in vitro and preclinical research applications.
When procuring synthetic peptides for academic or enterprise laboratory setups, verified chain-of-custody and stringent Quality Assurance (QA) protocols are critical. Substandard materials containing residual TFA salts, truncations, or endotoxin contamination can skew assay results and invalidate cellular data. PX1 Research addresses these experimental risks by maintaining fully transparent supply chains and distributing domestic reagents shipped directly from our California and Arizona fulfillment centers.
CJC-1295 No DAC is a modified peptide fragment derived from native Growth Hormone-Releasing Hormone (GHRH 1-29). The native 29-amino-acid chain of human GHRH is subject to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) in biological matrices. To overcome this chemical vulnerability in laboratory settings, researchers developed a tetrasubstituted variant featuring targeted amino acid substitutions at positions 2, 8, 15, and 27.
Specifically, substituting D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27 significantly enhances resistance to enzymatic cleavage while preserving full binding affinity for the GHRH receptor. Unlike its counterpart CJC-1295 with Drug Affinity Complex (DAC), CJC-1295 No DAC lacks the reactive maleimide-derived linker that binds bioconjugate proteins like albumin. Consequently, Modified GRF 1-29 exhibits a shorter plasma half-life (approximately 30 minutes in animal models), mimicking natural pulsatile pituitary secretion patterns rather than sustained basal elevation.
In vitro signal transduction studies show that CJC-1295 No DAC functions as a potent agonist at the G-protein-coupled growth hormone-releasing hormone receptor (GHRHR) located on pituitary somatotropes. Upon receptor binding, the compound activates the Gs alpha subunit, stimulating intracellular adenylate cyclase. This leads to an accumulation of cyclic adenosine monophosphate (cAMP) and subsequent activation of protein kinase A (PKA).
The PKA signaling pathway downstream induces calcium influx through L-type voltage-gated calcium channels, promoting exocytosis of pre-stored growth hormone (GH) secretory vesicles. Because CJC-1295 No DAC undergoes rapid metabolic clearance relative to bioconjugate analogs, it elicits discrete, transient GH release spikes. This short-acting pharmacokinetic profile makes it an essential probe for investigating physiological pulsatile secretion dynamics, somatotroph responsiveness, and feedback regulation via somatostatin. Researchers exploring broader pathways can review complete compound specifications across our catalog of all research peptides.
Preclinical rodent models demonstrate that administration of CJC-1295 No DAC elevates plasma GH concentrations within 15 to 30 minutes post-exposure, subsequently inducing hepatic expression of insulin-like growth factor 1 (IGF-1). IGF-1 acts as the primary mediator for many downstream physiological processes observed in GHRH axis studies, including cellular proliferation, protein synthesis, and extracellular matrix remodeling.
In animal models evaluating musculoskeletal and connective tissue repair, GHRH agonist exposure has been associated with accelerated collagen deposition, enhanced osteoblast activation, and improved nitrogen balance in nitrogen-wasted states. Researchers examining metabolic regulation also utilize Modified GRF 1-29 to measure lipid oxidation rates and glucose homeostatic adjustments downstream of transient GH spikes. Insights into GHRH receptor interactions and comparative peptide kinetics are further documented within the PX1 research library.
To select the appropriate secretagogue for specific experimental designs, investigators frequently compare GHRH agonists and ghrelin receptor (GHS-R) agonists based on structural modifications, half-life, and receptor selectivity. The table below outlines key technical differences among common research secretagogues available in our product catalog:
While CJC-1295 DAC contains a maleimide complex that extends biological half-life to several days via albumin conjugation, CJC-1295 No DAC maintains a short, physiological half-life without systemic accumulation. When evaluating early-generation GHRH fragments, researchers often examine Sermorelin, which represents the unmodified native 29-amino-acid chain and possesses lower enzymatic stability than Modified GRF 1-29. Additionally, investigators frequently combine GHRH agonists with selective growth hormone secretagogues such as Ipamorelin in dual-receptor activation studies to evaluate synergistic GH release, as detailed in our technical guide on Ipamorelin and CJC-1295 synergy.
For laboratory researchers evaluating peptide suppliers, analytical transparency is paramount. Substandard synthetic peptides frequently contain unreacted amino acids, deletion sequences, or residual cleavage reagents such as trifluoroacetic acid (TFA). To ensure raw material integrity, PX1 Research subjects every lot of CJC-1295 No DAC to rigorous analytical testing in independent ISO 17025 accredited testing facilities.
Purity is quantified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a baseline chemical purity exceeding 99.0%. Molecular weight and peptide sequence fidelity are confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS) and Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF). Every shipment from PX1 Research includes a lot-specific Certificate of Analysis (COA) containing raw chromatographic charts and spectral data, giving principal investigators full confidence in data reproducibility.
Bacterial endotoxins—specifically lipopolysaccharides (LPS) derived from Gram-negative outer cell membranes—pose a critical risk to cell culture assays and preclinical animal experiments. Exposure to trace endotoxin levels can trigger non-specific inflammatory signaling, alter cytokine expression profiles, and invalidate experimental biological endpoints.
PX1 Research enforces strict endotoxin control standards. Our CJC-1295 No DAC is manufactured under sterile conditions, purified through specialized preparatory columns, and subjected to standard Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain below stringent research thresholds (<0.1 EU/mg). Following purification, the peptide undergoes controlled lyophilization to form a stable, white freeze-dried cake, minimizing moisture content and preventing hydrolytic degradation during transit.
To maintain molecular stability during long-term storage, lyophilized CJC-1295 No DAC should be kept sealed at -20°C or -80°C in a desiccated environment away from light. Under these conditions, the dry peptide maintains chemical stability for extended periods. Prior to reconstituting in the lab, vials should be allowed to equilibrate to room temperature to prevent condensation from forming inside the container.
For reconstituting laboratory samples, analytical-grade Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Reconstitution Water should be introduced gently along the glass vial wall. The vial should be gently swirled—never vigorously shaken—until the cake dissolves completely into a clear solution. Reconstituted aliquots must be stored at 2°C to 8°C and used within defined experimental timeframes to prevent mechanical shearing or chemical hydrolysis. For additional technical protocols on peptide handling, consult our specialized GHRH analogs guide.
PX1 Research is committed to supporting domestic research infrastructure by providing USA-manufactured reagents produced under strict cGMP-compliant standards. By maintaining domestic facilities in California and Arizona, we eliminate international customs delays, temperature degradation risks, and supply chain bottlenecks that frequently disrupt academic and private research schedules.
Orders placed Monday through Friday before 12:00 PM PST are processed with same-day shipping, utilizing insulated packaging to preserve thermal integrity during transit. Principal investigators, laboratory managers, and corporate research departments seeking bulk procurement or custom synthesis services can establish dedicated procurement accounts through our wholesale lab portal.
What is the difference between CJC-1295 No DAC and CJC-1295 with DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex (DAC) maleimide linker. As a result, it does not bind to serum albumin, exhibiting a much shorter biological half-life (approximately 30 minutes) compared to CJC-1295 DAC (which has a half-life of 6–8 days). This allows researchers to study short, pulsatile spikes in GH release.
How does PX1 Research verify the purity of CJC-1295 No DAC?
Every lot of CJC-1295 No DAC undergoes third-party ISO 17025 laboratory verification. Purity is verified to be ≥99.0% using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), while sequence identity and molecular weight are confirmed using Mass Spectrometry (MS).
What endotoxin standards are maintained for CJC-1295 No DAC?
PX1 Research enforces strict endotoxin control, verifying through LAL testing that endotoxin levels remain below 0.1 EU/mg to prevent non-specific immunological responses during cell culture or preclinical animal assays.
Where does PX1 Research ship CJC-1295 No DAC from?
All orders are fulfilled directly from our USA-based facilities in California and Arizona. We offer same-day shipping for orders placed before 12:00 PM PST Monday through Friday.
How should lyophilized CJC-1295 No DAC be stored in the lab?
Lyophilized powder should be stored at -20°C or -80°C in a dry, dark environment. Once reconstituted with sterile or bacteriostatic water, liquid solutions should be kept refrigerated at 2°C to 8°C and used promptly according to research protocols.
Is CJC-1295 No DAC approved for human consumption or therapeutic use?
No. CJC-1295 No DAC is strictly synthesized and sold for in vitro, non-clinical, and laboratory research applications only. It is not approved for human or veterinary medical use, therapy, or diagnosis.
What diluent is recommended for reconstituting CJC-1295 No DAC?
In laboratory research settings, sterile bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection is typically used for reconstitution, depending on the specific cellular or animal model assay design.
Can institutions purchase CJC-1295 No DAC in bulk quantities?
Yes. Qualified academic institutions, biotechnology companies, and contract research organizations (CROs) can request high-volume pricing and lot reservation through the PX1 Research wholesale portal.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.